Transforming MS Care: Early Intervention and Sustained Safety

This promotional video is organised and funded by Bristol Myers Squibb. This information is for healthcare professionals only.

Prescribing and adverse event information for ozanimod▼ can be found at the bottom of this page. This symposium was organised and funded by Bristol Myer Squibb. BMS medicines and/or product information may be discussed.

The video presents a satellite symposium titled ‘Transforming MS Care: Early Intervention and Sustained Safety’ held at the 40^th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) discussed current challenges and future advances in the management of multiple sclerosis (MS). The symposium discussed the importance of early intervention with disease-modifying therapy (DMT) in people with MS. The session explored the effects of DMT switching in patients with MS, and discussed data on the persistence, patient satisfaction, and long-term safety associated with DMTs. The DAYBREAK OLE trial investigating once-daily ozanimod showed that early treatment with high-efficacy DMT is essential to improve disability outcomes, preserve cognition, and delay MS disease progression.

Speakers

Carrie M. Hersh
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA

Eva Kubala Havrdová
Charles University, Prague, Czechia

Klarissa Hanja Stürner
Christian-Albrecht University of Kiel, Germany

Ozanimod is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

Ozanimod® is subject to additional monitoring. This will allow quick identification of new safety information.

Prescribing information for HCPs in the UK can be found here.
Prescribing information for HCPs in Ireland can be found here.

2084-GB-2500024
May 2025